

NHL: Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Lymphoma Stage: __0 __0-E __0-X __0-XE __IA __IA-E __IA-X __IA-XE __IB __IB-E __IB-X __IB-XE __IIA __IIA-E __IIA-X __IIA-XE __IIB __IIB-E __IIB-X __IIB-XE __IIIA __IIIA-E __IIIA-X __IIIA-XE __IIIB __IIIB-E __IIIB-X __IIIB-XE __IVA __IVA-E __IVA-X __IVA-XE __IVB __IVB-E __IVB-X __IVB-XE __NS __Recurrent

Leukemia Stage: __NS (No stage) __Recurrent

Line of Treatment: __First Line __Second Line __Third Line __Third Line+ __Maintenance

ECOG Performance Status: __0 __1 __2 __3 __4

Biomarkers:

11q deletion: __Absent __Present

17p deletion: __Absent __Present

CD20 Status: __Negative __Positive

TP53 Status: __Mutation Absent __Mutation Present

First Line Therapy (1st line) | with 17p Deletion

Ibrutinib (Imbruvica)

First Line Therapy (1st line) | without 17p Deletion

FCR: fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (Rituxan)

Ibrutinib (Imbruvica)

Obinutuzumab (Gazyva) and chlorambucil (Leukeran)

Second and subsequent lines of therapy (2nd line +) | with 17p Deletion

Ibrutinib (Imbruvica)

Idelalisib (Zydelig)

Idelalisib (Zydelig) and rituximab (Rituxan)

Second and subsequent lines of therapy (2nd line +) | without 17p Deletion or Unspecified

FCR: fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (Rituxan)

Ibrutinib (Imbruvica)

Idelalisib (Zydelig)

Idelalisib (Zydelig) and rituximab (Rituxan)

Rituximab (Rituxan) and bendamustine (Bendeka, Treanda)

